Alnylam Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALNY Alnylam Pharmaceuticals Inc
NUV Nuveen Municipal Value Fund
NNBR NN Inc
WAT Waters Corp
ADP Automatic Data Processing Inc
CLABF Core One Labs Inc
FRHLF Freehold Royalties Ltd
WDAY Workday Inc
ENVX Enovix Corp
ENB Enbridge Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.

Closing Price
$148.50
Day's Change
0.50 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
152.42
Day's Low
142.69
Volume
(Light)
Volume:
457,129

10-day average volume:
740,048
457,129

Thermo Fisher Scientific Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

5:25 pm ET November 8, 2021 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Thermo Fisher Scientific Inc. (TMO) advanced 1.24% to $624.47 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.09% to 4,701.70 and the Dow Jones Industrial Average rising 0.29% to 36,432.22. The stock's rise snapped a two-day losing streak. Thermo Fisher Scientific Inc. closed $19.05 below its 52-week high ($643.52), which the company reached on November 4th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Danaher Corp. (DHR) rose 3.17% to $301.35, Intuitive Surgical Inc. (ISRG) rose 0.13% to $365.42, and Becton Dickinson & Co. (BDX) rose 0.64% to $245.27. Trading volume (1.2 M) remained 138,013 below its 50-day average volume of 1.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 8, 2021.

-MarketWatch Automation

	

(END) Dow Jones Newswires

November 08, 2021 17:25 ET (22:25 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.